While the reduction in price target from $19 to $18 by Canaccord Genuity could be seen as a negative adjustment, the maintenance of a Buy rating by analyst Whitney Ijem suggests a continued positive outlook on Tenaya Therapeutics. The impact on the stock price is likely neutral in the short term as the lowered price target is offset by the reaffirmed confidence in the company's prospects.